Michael Farrell - ResMed Insider

RMD -- USA Stock  

USD 106.66  3.68  3.57%

  CEO
Mr. Michael Farrell is Chief Executive Officer and Director of the company. Mr. Farrell was our chief executive officer and a director since March 1, 2013. Before that appointment, he served as our president Americas from May 2011 our senior vice president, strategic business unit sleep from July 2007 to May 2011 our vice president, marketing for the Americas from June 2005 through July 2007 and before that was our vice president, business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and steel manufacturing at Arthur D. Little, Genzyme Corporationrationration, Dow Chemical, and BHP Billiton. Mr. Farrell serves on the board of directors of Zimmer Biomet, a multibillion dollar public company that provides implantable musculoskeletal medical devices for patients globally. Mr. Farrell is a member of the Compensation and Management Development committee as well as the Nominating and Governance committee at Zimmer Biomet. Mr. Farrell also serves on the board of directors of the Advanced Medical Technology Association, based in Washington, DC. Mr. Farrell volunteers as a trustee for nonprofit organizations UC San Diego Foundation, Rady Childrens Hospital, the La Jolla Playhouse, and the Museum of Man
Age: 44  CEO Since 2013  MBA    
858-836-5000  http://www.resmed.com
Farrell holds a bachelor of engineering, with firstclass honours, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management.

Michael Farrell Latest Insider Activity

Management Efficiency

The company has Return on Asset of 10.72 % which means that on every $100 spent on asset it made $10.72 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.7 % implying that it generated $15.7 on every 100 dollars invested.
The company has 281.45 M in debt with debt to equity (D/E) ratio of 13.6 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 2.05 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Found 10 records

CEO Since

Rui ArashiyamaChina Cord Blood Corporation
N/A
Yue DengChina Cord Blood Corporation
N/A
Donald CaseyDENTSPLY SIRONA
2018
Dow WilsonVarian Medical Systems
2012
Mark ThiererDENTSPLY SIRONA
2017
Geoffrey RotsteinEquillium
2006
Jeffrey SlovinDENTSPLY SIRONA
2016
David CordaniCigna Corporation
2009
Michael McMullenAgilent Technologies
2015
Ting ZhengChina Cord Blood Corporation
2017

Entity Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and is traded on New York Stock Exchange. It employs 5940 people.ResMed (RMD) is traded on New York Stock Exchange in USA. It is located in 9001 Spectrum Center Boulevard and employs 5,940 people.

ResMed Leadership Team

John Wareham, Independent Director
Ronald Taylor, Lead Independent Director
Rob Douglas, President COO
Christopher Roberts, Independent Director
Gary Pace, Independent Director
Chris Roberts, Independent Director
Robert Douglas, Pres and COO
Agnes Lee, Senior Director - Investor Relations
Carol Burt, Independent Director
Rich Sulpizio, Independent Director
Peter Farrell, Non-Executive Chairman of the Board
Jim Hollingshead, President - Americas
Brett Sandercock, CFO and Principal Accounting Officer
Ron Taylor, Lead Independent Director
Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit
Jack Wareham, Independent Director
Anne Reiser, President Europe
Karen Drexler, Director
Raj Sodhi, President ? Software as a Service (SaaS) Business and CTO
David Pendarvis, Chief Admin. Officer, Global General Counsel and Secretary
Richard Sulpizio, Independent Director
Michael Farrell, CEO and Director
Richard McHale, President ? Respiratory Care
Donald Darkin, President ? innovation & operations

Stock Performance Indicators

Did you try this?

Run Portfolio Suggestion Now

   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Portfolio Suggestion
Currently Active Assets on Macroaxis
IVV   
Purchased over 100 shares of
few hours ago
Traded for 278.27
IJR   
Purchased over 10K shares of
few hours ago
Traded for 79.88
IJH   
Sold over 100 shares of
few hours ago
Traded for 187.94
IJH   
Sold over 100 shares of
few hours ago
Traded for 187.94
S   
Purchased over 400 shares of
few hours ago
Traded for 6.46
Additionally take a look at Your Equity Center. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.
Search macroaxis.com